Topical application of Cas9 ribonucleoproteins inhibits corneal neovascularization in a mouse model of alkali burn injury

1. Taylor AW. Ocular immune privilege. Eye. 2009;23:1885–9.

   Article  CAS  PubMed  PubMed Central  Google Scholar 

2. Cursiefen C, Chen L, Dana MR, Streilein JW. Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea. 2003;22:273–81.

   Article  PubMed  Google Scholar 

3. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharm. 2009;157:220–33.

   Article  CAS  Google Scholar 

4. Roshandel D, Eslani M, Baradaran-Rafii A, Cheung AY, Kurji K, Jabbehdari S, et al. Current and emerging therapies for corneal neovascularization. Ocul Surf. 2018;16:398–414.

   Article  PubMed  PubMed Central  Google Scholar 

5. Bachmann B, Taylor RS, Cursiefen C. Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology. 2010;117:1300–5.e7.

   Article  PubMed  Google Scholar 

6. Abdelfattah NS, Amgad M, Zayed AA, Hussein H, Abd El-Baky N. Molecular underpinnings of corneal angiogenesis: advances over the past decade. Int J Ophthalmol. 2016;9:768–79.

   PubMed  PubMed Central  Google Scholar 

7. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Investig Ophthalmol Vis Sci. 2000;41:2514–22.

   CAS  Google Scholar 

8. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Investig. 2004;113:1040–50.

   Article  CAS  PubMed  PubMed Central  Google Scholar 

9. Kim SW, Ha BJ, Kim EK, Tchah H, Kim T-i. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008;115:e33–e8.

   Article  PubMed  Google Scholar 

10. Benayoun Y, Adenis JP, Casse G, Forte R, Robert PY. Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study. Cornea. 2012;31:937–44.

    Article  PubMed  Google Scholar 

11. Sarah B, Ibtissam H, Mohammed B, Hasna S, Abdeljalil M. Intrastromal injection of bevacizumab in the management of corneal neovascularization: about 25 eyes. J Ophthalmol. 2016;2016.

12. Ferrari G, Dastjerdi MH, Okanobo A, Cheng SF, Amparo F, Nallasamy N, et al. Topical ranibizumab as a treatment of corneal neovascularization. Cornea. 2013;32:992–7.

    Article  PubMed  PubMed Central  Google Scholar 

13. Mergen B, Dogan C. Intrastromal aflibercept for the treatment of corneal neovascularization. Investig Ophthalmol Vis Sci. 2022;63:908–A0272-908 – A.

    Google Scholar 

14. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37:1847–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

15. Feizi S, Azari AA, Safapour S. Therapeutic approaches for corneal neovascularization. Eye Vis. 2017;4:28.

    Article  Google Scholar 

16. Cheng HC, Yeh SI, Tsao YP, Kuo PC. Subconjunctival injection of recombinant AAV-angiostatin ameliorates alkali burn induced corneal angiogenesis. Mol Vis. 2007;13:2344–52.

    PubMed  Google Scholar 

17. Lai LJ, Xiao X, Wu JH. Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model. J Biomed Sci. 2007;14:313–22.

    Article  CAS  PubMed  Google Scholar 

18. Uehara H, Zhang X, Pereira F, Narendran S, Choi S, Bhuvanagiri S, et al. Start codon disruption with CRISPR/Cas9 prevents murine Fuchs’ endothelial corneal dystrophy. eLife. 2021;10.

19. Hanlon KS, Kleinstiver BP, Garcia SP, Zaborowski MP, Volak A, Spirig SE, et al. High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat Commun. 2019;10:4439.

    Article  PubMed  PubMed Central  Google Scholar 

20. Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020;21:255–72.

    Article  CAS  PubMed  Google Scholar 

21. Wang D, Zhang F, Gao G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell. 2020;181:136–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

22. Nguyen GN, Everett JK, Kafle S, Roche AM, Raymond HE, Leiby J, et al. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat Biotechnol. 2021;39:47–55.

    Article  CAS  PubMed  Google Scholar 

23. Kim K, Park SW, Kim JH, Lee SH, Kim D, Koo T, et al. Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration. Genome Res. 2017;27:419–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

24. Chen G, Abdeen AA, Wang Y, Shahi PK, Robertson S, Xie R, et al. A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing. Nat Nanotechnol. 2019;14:974–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

25. Wang Y, Shahi PK, Xie R, Zhang H, Abdeen AA, Yodsanit N, et al. A pH-responsive silica–metal–organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries. J Control Release. 2020;324:194–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

26. Jang HK, Jo DH, Lee SN, Cho CS, Jeong YK, Jung Y, et al. High-purity production and precise editing of DNA base editing ribonucleoproteins. Sci Adv. 2021;7.

27. Banskota S, Raguram A, Suh S, Du SW, Davis JR, Choi EH, et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell. 2022;185:250–65.e16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

28. Yin D, Ling S, Wang D, Dai Y, Jiang H, Zhou X, et al. Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice. Nat Biotechnol. 2021;39:567–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

29. Wei A, Yin D, Zhai Z, Ling S, Le H, Tian L, et al. In vivo CRISPR gene editing in patients with herpetic stromal keratitis. Mol Ther. 2023;31:3163–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

30. Park J, Lim K, Kim JS, Bae S. Cas-analyzer: an online tool for assessing genome editing results using NGS data. Bioinformatics. 2017;33:286–8.

    Article  CAS  PubMed  Google Scholar 

31. Giacomini C, Ferrari G, Bignami F, Rama P. Alkali burn versus suture-induced corneal neovascularization in C57BL/6 mice: an overview of two common animal models of corneal neovascularization. Exp Eye Res. 2014;121:1–4.

    Article  CAS  PubMed  Google Scholar 

32. Anderson C, Zhou Q, Wang S. An alkali-burn injury model of corneal neovascularization in the mouse. J Vis Exp. 2014.

33. Luisi J, Lin JL, Karediya N, Kraft ER, Sharifi A, Schmitz-Brown ME, et al. Concentration-associated pathology of alkali burn in a mouse model using anterior segment optical coherence tomography with angiography. Exp Eye Res. 2022;223:109210.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

34. Lu P, Li L, Liu G, Baba T, Ishida Y, Nosaka M, et al. Critical role of TNF-α-induced macrophage VEGF and iNOS production in the experimental corneal neovascularization. Investig Ophthalmol Vis Sci. 2012;53:3516–26.

    Article  CAS  Google Scholar 

35. Bai Y, Jiao X, Hu J, Xue W, Zhou Z, Wang W. WTAP promotes macrophage recruitment and increases VEGF secretion via N6-methyladenosine modification in corneal neovascularization. Biochim Biophys Acta Mol Basis Dis. 2023;1869:166708.

    Article  CAS  PubMed  Google Scholar 

36. Kim S, Kim D, Cho SW, Kim J, Kim J-S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014;24:1012–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

37. Fu YW, Dai XY, Wang WT, Yang ZX, Zhao JJ, Zhang JP, et al. Dynamics and competition of CRISPR-Cas9 ribonucleoproteins and AAV donor-mediated NHEJ, MMEJ and HDR editing. Nucleic Acids Res. 2021;49:969–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

38. Amador C, Shah R, Ghiam S, Kramerov AA, Ljubimov AV. Gene therapy in the anterior eye segment. Curr Gene Ther. 2022;22:104–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

39. Corliss BA, Azimi MS, Munson JM, Peirce SM, Murfee WL. Macrophages: an inflammatory link between angiogenesis and lymphangiogenesis. Microcirculation. 2016;23:95–121.

    Article  PubMed  PubMed Central  Google Scholar 

40. Giannaccare G, Pellegrini M, Bovone C, Spena R, Senni C, Scorcia V, et al. Anti-VEGF treatment in corneal diseases. Curr Drug Targets. 2020;21:1159–80.

    Article  PubMed  Google Scholar 

41. Bakunowicz-Łazarczyk A, Urban B. Assessment of therapeutic options for reducing alkali burn-induced corneal neovascularization and inflammation. Adv Med Sci. 2016;61:101–12.

    Article  PubMed  Google Scholar 

42. Mukwaya A, Mirabelli P, Lennikov A, Thangavelu M, Jensen L, Peebo B, et al. Repeat corneal neovascularization is characterized by more aggressive inflammation and vessel invasion than in the initial phase. Investig Ophthalmol Vis Sci. 2019;60:2990–3001.

    Article  CAS  Google Scholar 

43. Bastola P, Song L, Gilger BC, Hirsch ML. Adeno-associated virus mediated gene therapy for corneal diseases. Pharmaceutics. 2020;12:767.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

44. Miyadera K, Conatser L, Llanga TA, Carlin K, O’Donnell P, Bagel J, et al. Intrastromal gene therapy prevents and reverses advanced corneal clouding in a canine model of mucopolysaccharidosis I. Mol Ther. 2020;28:1455–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

45. Su W, Sun S, Tian B, Tai PWL, Luo Y, Ko J, et al. Efficacious, safe, and stable inhibition of corneal neovascularization by AAV-vectored anti-VEGF therapeutics. Mol Ther Methods Clin Dev. 2021;22:107–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

46. Chew WL, Tabebordbar M, Cheng JK, Mali P, Wu EY, Ng AH, et al. A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods. 2016;13:868–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

47. Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

48. Saika S, Ikeda K, Yamanaka O, Flanders KC, Nakajima Y, Miyamoto T, et al. Therapeutic effects of adenoviral gene transfer of bone morphogenic protein-7 on a corneal alkali injury model in mice. Lab Investig. 2005;85:474–86.

    Article  CAS  PubMed  Google Scholar 

49. Mohan RR, Sinha S, Tandon A, Gupta R, Tovey JC, Sharma A. Efficacious and safe tissue-selective controlled gene therapy approaches for the cornea. PLoS One. 2011;6:e18771.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

50. Gupta S, Rodier JT, Sharma A, Giuliano EA, Sinha PR, Hesemann NP, et al. Targeted AAV5-Smad7 gene therapy inhibits corneal scarring in vivo. PLoS ONE. 2017;12:e0172928.

    Article  PubMed  PubMed Central  Google Scholar 

51. Mohan RR, Martin LM, Sinha NR. Novel insights into gene therapy in the cornea. Exp Eye Res. 2021;202:108361.

    Article  CAS  PubMed  Google Scholar 

52. Ge Q, Zhang H, Hou J, Wan L, Cheng W, Wang X, et al. VEGF secreted by mesenchymal stem cells mediates the differentiation of endothelial progenitor cells into endothelial cells via paracrine mechanisms. Mol Med Rep. 2018;17:1667–75.

    CAS  PubMed  Google Scholar 

53. Ogunshola OO, Antic A, Donoghue MJ, Fan SY, Kim H, Stewart WB, et al. Paracrine and autocrine functions of neuronal vascular endothelial growth factor (VEGF) in the central nervous system. J Biol Chem. 2002;277:11410–5.

    Article  CAS  PubMed  Google Scholar 

54. Maruyama K, Ii M, Cursiefen C, Jackson DG, Keino H, Tomita M, et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Investig. 2005;115:2363–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

55. Detry B, Blacher S, Erpicum C, Paupert J, Maertens L, Maillard C, et al. Sunitinib inhibits inflammatory corneal lymphangiogenesis. Investig Ophthalmol Vis Sci. 2013;54:3082–93.

    Article  CAS  Google Scholar 

56. Cursiefen C, Cao J, Chen L, Liu Y, Maruyama K, Jackson D, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Investig Ophthalmol Vis Sci. 2004;45:2666–73.

    Article  Google Scholar 

Download references